Cellectis SA (CLLS) Stock AnalysisCLLSStock AnalysisCellectis SA

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others. It operates in the Healthcare sector.

Cellectis SA is a good buy right now due to its recent FDA RMAT designation for its CAR-T therapy, which has shown a 67% objective response rate in trials. The current price of $3.40 is significantly lower than the analyst price target of $9, suggesting substantial upside potential. Additionally, the stock has gained 23.64% over the last 20 days, indicating positive momentum. However, the forward P/E ratio is 0, reflecting uncertainty in earnings projections, which is a risk to consider.

6 analysts cover CLLS: 5 rate it Buy, 1 Hold and 0 Sell. The average price target is 7.00.